A
Aurinia Pharmaceuticals D
D
AUPH
7.34000
USD
-0.44
(-5.66%)
مغلق
حجم التداول
47,368
الربح لكل سهم
1
العائد الربحي
-
P/E
184
حجم السوق
1,008,068,377
الأخبار المقالات
العنوان: Aurinia Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.